Robotic-assisted retroperitoneal lymph node dissection for stage II testicular cancer

Objective:To evaluate the perioperative as well as early oncological outcomes of patients undergoing robotic retroperitoneal lymph node dissection for treatment of testicular cancer.Methods:We conducted a prospective consecutive case series of patients undergoing robotic assisted retroperitoneal lymph node dissection for metastatic testicular cancer between May 2018 and July 2021 at our institution.Data were collected on patient and tumour characteristics,intraoperative and postoperative parameters,and functional and oncological outcomes.Descriptive statistics are presented.Results:Nineteen patients were identified;18(94.7%)completed the procedure robotically and one was converted to open surgery;78.9%of patients had stage≥IIB and 12(63.2%)patients had undergone prior chemotherapy.The median operative time was 300(interquartile range[IQR]240-315)min.Median blood loss was 100(IQR 50-175)mL.Median length of stay was 2(range 1-11)days.All robotically completed patients commenced diet and passed flatus on Day 1 and were discharged by Day 3.The median lymph node yield was 40.5(IQR 38-51)nodes.All patients undergoing nerve-sparing procedures recovered antegrade ejaculatory function.One patient had a Clavien-Dindo III complication(chylous ascites requiring drainage).At a median follow-up of 22.3(IQR 16.3-24.9)months,one patient developed retroperitoneal recurrence,which was successfully treated with second-line chemotherapy;no other patients have had recurrences.Conclusion:Robotic retroperitoneal lymph node dissection is a safe and feasible alternative to open surgery in appropriately selected patients,offering low morbidity.Early oncological outcomes are promising.Larger cohorts and longer follow-ups are required to validate our institution's findings.

Management of Testicular Cancers in Brazzaville

Introduction: Testicular cancer accounts for 5% of urological tumors, predominantly affecting young men. The aim of our study was to report the diagnostic and evolutionary aspects of testicular cancer cases treated in our center. Patients and Methods: A retrospective study conducted over a 15-year period involving 12 patients treated for testicular cancer at the University Hospital of Brazzaville. Results: The median age was 31 years (range 11 to 49 years), with a median consultation delay of 10.6 months (range 3 to 27 months). Scrotal mass was the most common reason for consultation. Cancer was bilateral in two patients. Two patients were admitted with metastatic disease. Histopathological examination favored germ cell tumors in 7 cases, two cases of non-Hodgkin’s malignant lymphoma, and one case of epididymo-testicular adenocarcinoma. Adjuvant chemotherapy resulted in complete remission in patients with germ cell tumors. However, neoadjuvant chemotherapy was not effective in patients admitted with advanced-stage disease. Conclusion: Testicular cancer is a rare condition that is curable in the majority of cases, but its management is often complicated in our setting due to delayed diagnosis caused by taboos surrounding genital organ pathologies.

Testicular cancer in patients after treatment of cryptorchidism

Objective: We summarized the relationship between the descent of a testicle into the scrotum and testicular cancer.Methods: Twenty-eight patients with testicular cancer after surgical treatment of cryptorchidism were retrospective analysis.Results: All patients were performed surgical treatment of cryptorchidism from 2 to 28 years old (median,12 years;average,16 years).Testicular cancer age ranged from 19 to 53 years (median,33 years;average,36 years).Malignant transformation occurred from 3 to 25 years of operation time (average,18 years).Twenty-seven cases of malignant cryptorchidism ipsilateral,contralateral malignancy in 1 case,27 cases were underwent radical resection of testicular cancer.Pathology diagnosis was mainly seminoma.Retroperitoneal lymph node dissection was done in 3 cases,18 cases were chemotherapy and radiotherapy in 3 cases.Conclusion: The undescended testicle is the most common genital malformation in boys.When diagnosed,it should be treated as early as possible,but successful treatment appears not to lessen the risk of testicular cancer,patients must be closely monitored follow-up.

Thromboembolic events in metastatic testicular cancer treated with cisplatin-based chemotherapy

BACKGROUND Testicular germ cell tumor(TGCT)is the most curable solid tumor and most common cancer among men 18-39 years.While cisplatin-based chemotherapy has significantly lengthened the survival of patients with TGCT,it is associated with a high rate of thromboembolic events(TEE).AIM To summarize our single-center experience highlighting patients who were diagnosed with TGCT and received platinum-based chemotherapy,with special attention to those patients who suffered a TEE.METHODS A retrospective analysis of the medical records and imaging studies of 68 consecutive individuals who were diagnosed with TGCT and received platinumbased chemotherapy at our Institution in a metropolitan community between January 1,2014 and December 31,2019.RESULTS A total of 19(28%)patients experienced a TEE following orchiectomy which occurred during chemotherapy in 13(68%)of these patients.Patients with a higher pathologic stage(stage III)were significantly(P=0.023)more likely to experience a TEE compared to patients who had a lower stage.Additionally,patients who were treated with 3 cycles of bleomycine,etoposide,and cisplatin and 1 cycle of etoposide and cisplatin or 4 cycles of etoposide and cisplatin were significantly 5(P=0.02)times more likely to experience a TEE compared to patients who were treated with only 3 cycles of bleomycine,etoposide,and cisplatin.CONCLUSION Due to numerous factors that predispose to a TEE such as large retroperitoneal disease,higher clinical stage,greater number of chemotherapy cycle,central venous catheter,cigarette smoking,and possible cannabis use,high-risk ambulatory patients with TGCT treated with cisplatin-based chemotherapy may benefit from prophylactic anticoagulation.Randomized studies to evaluate the safety and efficacy of prophylactic anticoagulants are warranted in this young patient population generally devoid of medical co-morbidities.

Tumour lysis syndrome:A rare acute presentation of locally advanced testicular cancer--Case report and review of literature

Tumour lysis syndrome(TLS)is a potentially fatal complication of malignancy or its treatment.This uncommon syndrome comprises laboratory findings of hyperuricaemia,hypocalcaemia,hyperkalaemia and hyperphosphataemia.A literature search revealed a total of eight patients,with testicular cancer,who had TLS.All these patients had metastatic disease.We present a unique case of a 47-year-old gentleman we saw in clinic,who presented with a rapidly growing right groin mass and acute breathlessness,and discuss the diagnosis and management of TLS.TLS is extremely rare in testicular cancer but necessitates the awareness of urologists.TLS can occur spontaneously in testicular malignancy.Cell lysis in a rapidly proliferating germ cell tumour is a possible mechanism.The prompt identification and institution of management for TLS is crucial to improve clinical outcomes.

Risk of second primary cancers after testicular cancer in East and West Germany： a focus on contralateral testicular cancers

Testicular cancer survival rates improved dramatically after cisplatin-based therapy was introduced in the 1970s. However, chemotherapy and radiation therapy are potentially carcinogenic. The purpose of this study was to estimate the risk of developing second primary cancers including the risk associated with primary histologic type （seminoma and non-seminoma） among testicular cancer survivors in Germany. We identified 16 990 and 1401 cases of testicular cancer in population-based cancer registries of East Germany （1961-1989 and 1996-2008） and Saarland （a federal state in West Germany; 1970-2008）, respectively. We estimated the risk of a second primary cancer using standardized incidence ratios （SIRs） with 95% confidence intervals （95% Cls）. To determine trends, we plotted model-based estimated annual SIRs. In East Germany, a total of 301 second primary cancers of any location were observed between 1961 and 1989 （SIR： 1.9; 95% Ch 1.7-2.1）, and 159 cancers （any location） were observed between 1996 and 2008 （SIR： 1.7; 95% Ch 1.4-2.0）. The SIRs for contralateral testicular cancer were increased in the registries with a range from 6.0 in Saarland to 13.9 in East Germany. The SIR for seminoma, in particular, was higher in East Germany compared to the other registries. We observed constant trends in the model-based SIRs for contralateral testicular cancers. The majority of reported SIRs of other cancer sites including histology-specific risks showed low precisions of estimated effects, likely due to small sample sizes. Testicular cancer patients are at increased risk especially for cancers of the contralateral testis and should receive intensive follow-ups.

RELATIONSHIP BETWEEN THE INCIDENCE RATES OF TESTICULAR AND PROSTATIC CANCERS AND FOOD CONSUMPTIONS

Objective: To determine the relationships between the incidence rates of testicular and prostatic cancers and food consumptions in order to study the etiologic cause and the mechanism of the development of male genital organ cancer. Methods: The incidence rates of testicular and prostatic cancers in 42 countries (region) were correlated with the dietary practices in these countries. These data came from the cancer rate database (1988–1992) and the food supply database (1961–1990) provided by the Department of Environmental Health, Medical University of Yamanashi, Japan. Results: The incidence rates of testicular and prostatic cancers varied greatly from country to country but in China the rates of the both malignancies were lower than that of USA and Japan. This may be due to the difference in lifestyle, especially in dietary practices. Among the food items we examined, cheese was most closely correlated with the incidence of testicular cancer at ages 20–39, followed by animal fats and milk. The correlation coefficient (r) was the highest (r=0.804) when calculated for cheese consumed during the period of 1961–1965 (maternal or prepubertal consumption). Stepwise-multiple-regression analysis revealed that cheese (1961–1965) made a significant contribution to the incidence of testicular cancer. Multiple coefficient (r) is 0.920. As far as prostatic cancer was concerned, milk was most closely correlated (r=0.711) with its incidence, followed by meat and coffee. Stepwise-multiple-regression analysis identified milk, meat, butter and coffee as significant factors contributing to the incidence of prostatic cancer (R=0.993). The results of our study suggest a role of milk and dairy practices in the development of testicular and prostatic cancers.

Programmed cell death protein 4 expression in renal cell carcinoma, penile carcinoma and testicular germ cell cancer

AIM:To investigate the expression of programmed cell death 4(Pdcd4)tumor suppressor gene in tissue specimen of renal cell carcinoma(RCC),testicular germ cell cancer and penile cancer.METHODS:Pdcd4 expression was studied using immunohistochemistry in 188 cases of RCC and 28 controls(including 9 oncocytoma);in 74 cases of penile carcinoma(including 17 metastatic tissue samples)and26 controls;in 11 cases of seminoma,in 14 cases of non-seminoma and 5 controls.RESULTS:Control tissues exhibited strong core and cytoplasmatic Pdcd4 staining.In contrast,core and cy-toplasmatic Pdcd4 levels were significantly decreased in cancer tissues.CONCLUSION:Our data support a role for Pdcd4(down-)regulation in urologic tumors.Interestingly,Pdcd4 expression seem to be a potential diagnostic marker for renal or penile tumors.

1990-2019年中国睾丸癌疾病负担分析

目的分析1990-2019年中国睾丸癌疾病负担及变化趋势。方法基于2019年全球疾病负担数据库(GBD 2019),分析1990-2019年中国人群睾丸癌的发病、死亡、伤残调整寿命年(DALYs)、过早死亡损失寿命年(YLLs)、伤残损失寿命年(YLDs)及其变化趋势。通过计算年估计变化百分比(EAPC)评估年龄标准化率(ASR)的变化。按照年龄分组,分析睾丸癌疾病负担的年龄分布特点。结果2019年中国睾丸癌发病例数为17.17×103例,死亡例数为1.21×103例,年龄标准化发病率为2.39/10万,年龄标准化死亡率为0.16/10万。与1990年相比,发病例数、死亡例数、年龄标准化发病率均明显增加或增高,与全球变化趋势一致,而增幅均高于全球水平,但中国和全球年龄标准化死亡率均呈现下降趋势。1990-2019年,中国睾丸癌的DALYs、YLLs、YLDs均明显上升,分别增加了29.66%、9.83%、720.91%。0~15岁和30~35岁是睾丸癌高发的两个年龄段,30~35岁是我国睾丸癌疾病负担最重的年龄段。结论1990-2019年中国睾丸癌的疾病负担整体呈上升趋势。儿童和青壮年发病率较高、疾病负担较重,应作为睾丸癌的重点筛查及防治人群。

基于年龄-时期-队列模型的中国睾丸癌疾病负担研究

目的分析1990-2019年中国睾丸癌的发病和死亡情况,并探讨年龄、时期和队列效应对睾丸癌发病和死亡的影响。方法利用全球疾病负担(Global Burden of Disease,GBD)2019数据库,分析1990-2019年中国睾丸癌发病和死亡情况,应用Joinpoint软件分析标化发病率和标化死亡率的时间变化趋势,计算平均年度变化百分比。构建年龄-时期-队列模型,分析年龄、时期和出生队列效应对睾丸癌发病及死亡趋势变化的影响。结果2019年,中国睾丸癌发病率为1.21/10万,死亡率为0.08/10万,发病率和死亡率比1990年升高了348.15%和14.29%。1990-2019年,中国睾丸癌标化发病率呈升高趋势,平均每年升高5.23%,趋势有统计学意义(P<0.05),睾丸癌标化死亡率呈下降趋势,平均每年下降0.12%,但趋势无统计学意义(P>0.05)。年龄效应结果显示,1990-2019年中国睾丸癌的发病率和死亡率整体呈升高趋势,发病率和死亡率均在60岁以后呈快速升高趋势,在85岁以上年龄组达到高峰。时期效应结果显示,1990-2019年,中国睾丸癌发病风险的时期变化相对危险度(relative ratio,RR)呈升高趋势,在2015-2019年发病风险最高,发病风险RR=2.44[95%可信区间(confidence interval,CI)2.31~2.56];睾丸癌死亡风险的时期变化RR值趋势呈下降趋势,1995-1999年死亡风险最高,死亡风险RR=1.09(95%CI 0.99~1.19)。队列效应结果显示,出生越晚的人,发病风险越高,死亡风险越低。结论1990-2019年,中国居民睾丸癌的标化发病率呈升高趋势,标化死亡率呈下降趋势但无统计学意义。不同年龄、时期和出生队列的睾丸癌流行病学模式和趋势可能为公共卫生提供新的见解,这些发现可为进一步减轻睾丸癌负担的公共卫生策略的制定提供重要依据。

Fertility outcome of patients with testicular tumor： before and after treatment

Testicular cancer （TC） is the most curable type of cancer, with a survival rate of more than 95%. Oncologists are faced with the challenge that gonadotoxic cancer treatments can compromise future fertility, either temporarily or permanently. Our aim was to investigate the long-term effects of TC treatments on male fertility and on the offspring of patients who had received these treatments. Between January 1996 and December 2010, 125 eligible patients, ranging from 18 to 54 years （median age 36.3 _＋ 15.7）, with unilateral TC underwent surgery, chemotherapy or radiotherapy at our center. Some of these patients had their semen samples cryopreserved in the Shanghai Human Sperm Bank. The clinical data were evaluated, and questionnaire and telephone follow-up surveys were given to all patients. The data were analyzed to determine the patients＇ fertility status pre- and posttreatment. Of the 125 eligible patients, 93.6% （117/125） were accessible and were evaluated. Among 81 men who were married before diagnosis, 21 had conceived successfully before diagnosis and six reported azoospermia. Posttreatment conception was attempted by 73 men; of these, 16 conceived naturally and 19 conceived by artificial reproductive techniques, resulting in 37 healthy babies with no congenital malformations. Of the patients who had not conceived before treatment, 21.9% （21/96） banked their sperm and 23.8% of these patients （5/21） subsequently used the banked sperm. Retroperitoneal lymph node dissection, chemotherapy and radiotherapy were the most highly correlated with lack of conception to TC patients with the desire for biological conception. There is no birth defects or childhood malignancies. post-TC treatment. Sperm banking should be recommended evidence to suggest that TC treatments are associated with

人类示指与环指指长比与男性生殖系统癌症相关性的研究进展

人类示指与环指指长比(2D∶4D)是产前性激素(雌激素/雄激素)暴露水平及敏感性的宏观标记物之一,在性别间差异明显。产前性激素暴露对出生后个体的心理特征、运动能力及多种性激素相关疾病均有影响。本研究综述了2D∶4D与男性生殖系统癌症(前列腺癌和睾丸癌)相关性的研究进展,以期为此类疾病的早期筛查提供参考信息。

A rare diagnosis:testicular dysgenesis with carcinoma in situ detected in a patient with ultrasonic microlithiasis

A rare case is presented where a dysgenetic testis with microinvasive carcinoma in situ （CIS, also known as intratubular germ cell neoplasm of unclassified type [IGCNU] and testicular intraepithelial neoplasia [TIN]） with microinvasion to rete testis and the interstitial tissue was found in a 32-year-old man presenting with mild scrotal pain and ultrasonic testicular microlithiasis. Knowledge of the association of ultrasound and CIS is important to diagnose patients at the stage prior to development of an overt germ cell tumor. The patient had three of four disorders considered symptoms of the testicular dysgenesis syndrome （TDS）： a dysgenetic left testicle with CIS, a mild left-sided cryptorchidism （high positioned scrotal hypotrophic testis） and a slightly reduced semen quality. Therefore, it should be kept in mind that a patient with one TDS symptom may harbour the other, even CIS or testicular cancer. Accordingly, patients with one TDS symptom ought to be examined for the presence of the others, and if more that one is present, extra concern is warranted.

Clinical outcomes in patients with stage non-seminomatous germ cell cancer

This study assesses the long-term outcomes in Han Chinese patients with clinical stage I non-seminomatous germ cell testicular cancer （CSI NSGCT） treated with surveillance, retroperitoneal lymph node dissection （RPLND） and adjuvant chemotherapy. We retrospectively evaluated 89 patients with a mean age of 26.5 years. After orchiectomy, 37 patients were treated with surveillance, 34 underwent RPLND and 18 were managed with chemotherapy. The overall survival rate, the recurrence-free survival rate and the risk factors were evaluated. The median follow-up length was 92 months （range： 6-149 months）. Thirteen of the 89 patients （14.6%） had relapses, and one died by the evaluation date. The overall survival rate was 98.9%. The cumulative 4-year recurrence-free rates were 80.2%, 92.0% and 100% for the surveillance, RPLND and chemotherapy groups, respectively. The disease-free period tended to be briefer in patients with a history of cryptorchidism and those with stage Is. Therefore, surveillance, RPLND and adjuvant chemotherapy might be reliable strategies in compliant patients with CSI NSGCT. Surveillance should be recommended for patients with the lowest recurrence rate, especially those without lymphovascular invasion. This study might aid the establishment of a standard therapy for CSI NSGCT in China.

前列腺癌睾丸转移2例报告并文献复习

回顾性分析前列腺癌睾丸转移病例2例,以提高对该病认识。报告2例前列腺癌睾丸转移的诊疗及随访情况,并结合国内外文献进行回顾性分析。2例患者均发生了全身多发淋巴结,骨及睾丸癌转移,随访至患者死亡。前列腺癌最常见的转移部位是骨,易发生中轴骨转移,到晚期常有多处转移,但发生睾丸转移的病例较为罕见。对于晚期前列腺癌应做包括睾丸在内的细致的检验检查,以防遗漏睾丸转移病灶。

Can serum tumor marker densities according to tumor volume and testicle size be used to predict progression in patients with testicular cancer?

Background The objective of this study is to determine the role of tumor marker density(TMD)values such as alpha-fetoprotein tumor volume ratio(ATVR),beta-human chorionic gonadotropin tumor volume ratio(βTVR),alpha-fetoprotein testicle size ratio(ATSR),beta-human chorionic gonadotropin testicle size ratio(βTSR),lactate dehydrogenase tumor volume ratio(LTVR),and lactate dehydrogenase testicle size ratio(LTSR)in the determination of progression-free survival(PFS)in patients with testicular cancer.Materials and methods A retrospective study was conducted of 95 patients followed-up in our clinic with a diagnosis of testicular cancer between January 2015 and August 2022.Patients were grouped according to clinical stage,as either early stage(n=50)or advanced stage(n=45).Clinical and pathological data and TMD values for all patients were recorded.Results The median age of patients was 35 years(21–63 years).All TMDs except LTVR in advanced stage patients were found to be significantly higher than those of early stage patients(p<0.05).Median ATVR(2.58 vs.0.0),ATSR(0.63 vs.0.03),βTVR(0.9 vs.0.009),andβTSR(0.18 vs.0.007)of the nonseminoma patients were found to be significantly higher than those of the seminoma patients,respectively(p<0.001).Progression-free survival(months)was decreased in seminoma patients with high values ofβTVR(11.3±1.9 vs.35.2±0.7),βTSR(16.2±3.4 vs.35.2±0.75),LTVR(17.7±3.4 vs.35.2±0.7),and LTSR(21.5±3.13 vs.35.09±0.8)(p<0.001).Decreased PFS(months)was associated with higher values of ATVR(5.37±0.7 vs.35.05±0.93),βTVR(7.4±1.5 vs.34.6±1.3),ATSR(5.37±0.75 vs.35.05±0.9),βTSR(7±1.5 vs.34.6±1.3),and LTSR(7.9±1.2 vs.34.3±1.5)in nonseminoma patients(p<0.001).Based on multivariate analysis,βTVR-LTVR and ATVR-ATSR were determined to be independent risk factors for reduced PFS in seminoma and nonseminoma patients,respectively(p<0.05).Conclusions The results of this study suggest that the calculation of TMDs could be a promising and simple method for prediction of PFS among testicular cancer patients.

Assessment of Prognostic Factors of Racial Disparities in Testicular Germ Cell Tumor Survival in the United States(1992–2015)

Objective Testicular germ cell tumors(TGCT) are the most common cancer among men aged 15 to 39 years. Previous studies have considered factors related to TGCT survival rate and race/ethnicity, but histological type of the diagnosed cancer has not yet been thoroughly assessed.Methods The data came from 42,854 eligible patients from 1992 to 2015 in the Surveillance Epidemiology and End Results 18. Frequencies and column percent by seminoma and nonseminoma subtypes were determined for each covariates. We used Cox proportional hazard regression to assess the impact of multiple factors on post-diagnostic mortality of TGCT.Results Black males were diagnosed at a later stage, more commonly with local or distant metastases.The incidence of TGCT in black non-seminoma tumors increased most significantly. The difference in survival rates between different ethnic and histological subtypes, overall survival(OS) in patients with non-seminoma was significantly worse than in patients with seminoma. The most important quantitative predictor of death was the stage at the time of diagnosis, and older diagnostic age is also important factor affecting mortality.Conclusion Histological type of testicular germ cell tumor is an important factor in determining the prognosis of testicular cancer in males of different ethnic groups.

Occlusive Syndrome Revealing a Nonseminoma Germ Cell Tumor Metastatic Testicular

Testicular cancer is rare. The authors report the case of a young Senegalese 21, who has consulted for an occlusive syndrome evolving for 48 hours that prompted his hospitalization. Note that the patient has consulted several times to persistent inguinal scrotal pain, a big right purse with chronic analgesic requirements and anti-inflammatory. Occlusive before this table, abdominal pelvic CT was performed and highlighted the presence of lung metastases, a large pelvic lymph node casting bridging the inter vesico-rectal space and responsible for extrinsic compression of the small intestine, lymph node inter casting aorto-cellar and latero aortic liver and multiple secondary locations. Faced with this bundle of arguments, clinical and laboratory, metastatic testicular tumor was raised and measured tumor markers. A right orchiectomy by inguinal was made with histology: A non-seminomatous germ cell tumor stage III. After orchiectomy germinal markers were still high and there was the problem of persistent occlusive syndrome despite resuscitation. A chemotherapy regimen was initiated with 4 cycles of chemotherapy according to the protocol BEP (bleomycin, etoposide, cisplatin). A significant regression of occlusive syndrome with a decline in clinical symptoms was noted. The revaluation at 3 months, 6 months and 1 year were highlighted: A normal clinical examination associated with a persistent correction rate of germline markers and lack of active lesion at thoraco-abdominopelvic CT.

术前中性粒细胞与淋巴细胞比值对睾丸生殖细胞肿瘤预后的预测价值

目的:探讨术前中性粒细胞与淋巴细胞比值(neutrophil to lymphocyte ratio,NLR)对睾丸生殖细胞肿瘤(testicular germ cell tumors,TGCT)患者预后的预测价值。方法:收集2016年01月至2023年10月于潍坊市人民医院行睾丸根治术的TGCT患者的临床及随访资料。通过受试者工作特征曲线(ROC)确定NLR的最佳截断值,用Kaplan-Meier法绘制生存曲线,比较高、低NLR组间的癌症特异性生存率(CSS)和无进展生存率(PFS)差异。采用Cox比例风险模型筛选影响CSS和PFS的独立危险因素。结果:共纳入33例患者,包括21例(63.6%)精原细胞瘤和12例(36.4%)非精原细胞瘤。Kaplan-Meier分析结果表明:高NLR预示着更差的CSS(P<0.001)和PFS(P<0.001)。Cox多因素分析显示:高NLR(HR=18.225,95%CI:1.806~183.859,P=0.014)是CSS的独立预后危险因素;高NLR(HR=11.371,95%CI:1.751~73.847,P=0.011)也是PFS的独立预后危险因素。结论:术前NLR高值是影响TGCT患者预后的独立预后危险因素,NLR越高患者的CSS和PFS越差。

Survival analysis of children with stage Ⅱ testicular malignant germ cell tumors treated with surgery or surgery combined with adjuvant chemotherapy

For children with stage II testicular malignant germ cell tumors(MGCT), the survival is good with surgery and adjuvant chemotherapy. However, there is limited data on surgical results for cases in which there was no imaging or pathologic evidence of residual tumor, but in which serum tumor markers either increased or failed to normalize after an appropriate period of half-life time post-surgery. To determine the use of chemotherapy for children with stage II germ cell tumors, we analyzed the outcomes(relapse rate and overall survival) of patients who were treated at the Sun Yat-sen University Cancer Center between January 1990 and May 2013. Twenty-four pediatric patients with a median age of 20 months(range, 4 months to 17 years) were enrolled in this study. In 20 cases(83.3%), the tumors had yolk sac histology. For definitive treatment, 21 patients underwent surgery alone, and 3 patients received surgery and adjuvant chemotherapy. No relapse was observed in the 3 patients who received adjuvant chemotherapy, whereas relapse occurred in 16 of the 21 patients(76.2%) treated with surgery alone. There were a total of 2 deaths. Treatment was stopped for 1 patient, who died 3 months later due to the tumor. The other patient achieved complete response after salvage treatment, but developed lung and pelvic metastases 7 months later and died of the tumor after stopping treatment. For children treated with surgery alone and surgery combined with adjuvant chemotherapy, the 3-year event-free survival rates were 23.8% and 100%, respectively(P = 0.042), and the 3-year overall survival rates were 90.5% and 100%, respectively(P = 0.588). These results suggest that adjuvant chemotherapy can help to reduce the recurrence rate and increase the survival rate for patients with stage II germ cell tumors.